Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aecom (ACM) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Aecom vs Amylx Pharmaceuticals Inc — how do they compare? Aecom trades at $67.13 (market cap $9.42B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B). The key difference: Aecom is far larger — about 3.7× Amylx Pharmaceuticals Inc's market cap, and Aecom pays a 1.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

ACMAMLX
Market Cap
$9.42B$2.53B
Sector
IndustrialsHealth
52-Week High
$134.35$24.19
52-Week Low
$66.86$7.82
Enterprise Value
$11.60B$2.28B
Dividend Yield
1.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aecom

ACM trades at $75.84, up 1.21% daily, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings missed expectations with a loss of $0.50 per share, though revenue trends remain stable near $16 billion annually. The company secured new infrastructure projects in Australia and Portugal, supporting a record backlog. Valuation metrics show a P/E of 15.83 and P/S of 0.63, below sector averages, indicating potential undervaluation.

Outlook is mixed: strong analyst consensus (64% buy) and a $99.20 price target suggest 31% upside, but Q2 miss and rising debt-to-asset ratio (22.61% in 2025) pose risks. Investors should weigh robust contract wins against earnings volatility and macroeconomic pressures on infrastructure spending.

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aecom

Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.

Read more on ACM

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX